Fresenius Medical Care AG & Co. KGaA

  • WKN: 578580
  • ISIN: DE0005785802
  • Land: Deutschland

Nachricht vom 08.07.2019 | 14:00

Fresenius Medical Care AG & Co. KGaA: Release of a capital market information

Fresenius Medical Care AG & Co. KGaA / Announcement pursuant to Art. 5 para. 1 lit. b), para. 3 of Regulation (EU) No 596/2014 and Art. 2 para. 3 of Delegated Regulation (EU) 2016/1052

08.07.2019 / 14:00
Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


- Share buy-back - 3rd Interim Report

In the period from July 1, 2019 until and including July 5, 2019, a total of 191,565 shares were repurchased within the framework of the share buy-back programme of Fresenius Medical Care AG & Co. KGaA ('Fresenius Medical Care') announced on June 14, 2019 pursuant to Art. 5 para. 1 lit. a) of Regulation (EU) No 596/2014 and Art. 2 para. 1 of Delegated Regulation (EU) 2016/1052.

The purchase was carried out exclusively by a credit institution commissioned by Fresenius Medical Care via the XETRA trading platform on the Frankfurt Stock Exchange:

Day of repurchase Aggregated volume in number of shares Weighted average share price
in EUR
01/07/2019 19,379 70.56205
02/07/2019 47,172 70.42499
03/07/2019 35,475 70.96543
04/07/2019 43,100 70.59706
05/07/2019 46,439 70.67572

The total volume of shares repurchased within the framework of this share buy-back in the period from June 17, 2019 until and including July 5, 2019 therefore amounts to 696,237 shares.

Detailed information on the transactions pursuant to Art. 2 para. 3 of Delegated Regulation (EU) 2016/1052 is available on Fresenius Medical Care's website at www.freseniusmedicalcare.com under section Investors.

Fresenius Medical Care AG & Co. KGaA
represented by Fresenius Medical Care Management AG
represented by its Management Board

Bad Homburg v.d.H., July 8, 2019



08.07.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Fonds Research 2019: Dt. Mittelstandsanleihen FONDS bietet attraktive Anlagemöglichkeit

Auch 2019 hat die GBC AG unter der Vielzahl an Publikumsfonds neun „Fonds Champions“ herausgefiltert. Darunter den Deutsche Mittelstandsanleihen FONDS (ISIN: LU0974225590), der eine qualitätsorientierte Strategie verfolgt und eine vielversprechende Anlagemöglichkeit in den deutschen Mittelstand bietet. Insbesondere vor dem Hintergrund des aktuellen Niedrigzinsniveaus sehen wir den Fonds als gute Chance, um attraktive Renditen zu erwirtschaften und dies verbunden mit einer traditionell niedrigen Fonds-Volatilität. Wir vergeben 5 von 5 GBC-Falken ein.

Aktuelle Research-Studie

Original-Research: dynaCERT Inc (von GBC AG): BUY dynaCERT Inc

20. September 2019